Table A1.
Summary of Neuropsychological Test Battery
| Group | Impairment Criterion (%) |
|
|---|---|---|
| ≥ 1.5 SDs on ≥ Two Tests or ≥ 2.0 SDs on ≥ One Test | ≥ 2.0 SDs on ≥ One Test | |
| ADT+ | ||
| Baseline | 50 | 41 |
| 6 months | 48 | 43 |
| 12 months | 56 | 50 |
| ADT− | ||
| Baseline | 38 | 31 |
| 6 months | 37 | 30 |
| 12 months | 32 | 23 |
| CA− | ||
| Baseline | 41 | 37 |
| 6 months | 28 | 25 |
| 12 months | 31 | 23 |
Abbreviations: ADT+, patients with prostate cancer receiving androgen-deprivation therapy; ADT−, patients with prostate cancer not receiving androgen-deprivation therapy; CA−, participants without prostate cancer; SD, standard deviation.